期刊文献+

pcDNA3.0/ATP7B对TX小鼠肝铜代谢影响 被引量:1

Effect of copper metabolism of pcDNA3.0/ATP7B on TX mice
下载PDF
导出
摘要 目的探索以重组真核表达质粒pcDNA3.0/ATP7B进行TX小鼠基因治疗的初步疗效。方法以质粒和脂质体混合后进行尾静脉注射,分别给予TX小鼠pcDNA3.0/APT7B 0、10、20、50、100、150μg,3 d后测定其肝铜含量(ng/mg,即每mg干重的肝组织中铜的含量),确定合适的治疗剂量。然后随机选取36只TX小鼠,随机分成3组,即注射生理盐水组、注射pcDNA3.0组、注射pcDNA3.0/ATP7B组。进行肝脏组织RT-PCR、W estern b lot检测和肝铜含量测定。结果根据预实验结果,取pcDNA3.0/APT7B 100μg/只为治疗剂量。RT-PCR和W estern b lot结果显示,加入pcDNA3.0/ATP7B组于加入后第3、7、14天均可见阳性条带。但以加入第3天时最明显。加入生理盐水组和加入pcDNA3.0质粒组均未见阳性条带。加入pcDNA3.0/APT7B组与生理盐水组及pcDNA3.0组比较,于加入第3、7天肝铜含量显著下降(P<0.05),以第3天下降最明显。加入第14天肝铜含量无显著下降,P>0.05。结论ATP7B基因重组真核表达质粒pcDNA3.0/ATP7B对TX小鼠的铜代谢有改善作用。 Objective To explore the impact of copper metabolism of pcDNA3.0/ATP7B on TX mice. Methods pcDNA3. 0/ATPTB was mixed with liposome,and administered into TX mice by tail vein injection. The dosage of pcDNA3.0/ATPTB was 100 p.g each mice. 36 TX mice were selected and divided into 3 groups randomly: group of physiologic saline, group of pcDNA3.0 and group of pcDNA3.0/ATP7B group. On the 3rd, 7th, 14th day, RT-PCR, Western blot, the liver copper index were conducted to investigat whether ATP7 B was expressed and the copper metabolism disturbance was ameliorated in TX mice. Results The human ATP7B proteins were detectable in pcDNA3.0/ ATP7B group,but not in the other two groups. The same results were got in RT-PCR part. On the 3rd,7th day,the liver copper index were significantly ameliorated in pcDNA3.0/ATP7B group than in the other two groups. On14th day,the liver copper index was not significantly decreased in pcDNA3.0/ATP7B group. Conclusion pcDNA3.0/ATP7B could ameliorate the copper metabolism disturbance in TX mice.
出处 《中国临床保健杂志》 CAS 2008年第2期175-177,225,共4页 Chinese Journal of Clinical Healthcare
基金 国家自然科学基金项目(3040147)
关键词 肝豆状核变性 质粒 转染 基因疗法 小鼠 Hepatolenticular degeneration Plasmids Transfection Gene therapy Copper Mice
  • 相关文献

参考文献7

二级参考文献26

  • 1Higuchi M, Fokin A, Masters TN, et al. Transport of colloidal particlas in lymphatics and vasculature after subcutaneous injection[ J ]. J Appl Physiol, 1999, 86:1381-1387.
  • 2Oussoren C, Velinova M, Scherphof G, et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. IV. Fate of liposomesin regional lymph nodes[J]. Biochim Biophys Aeta, 1998,1370:259-272.
  • 3Bethune C, Blum A, Geyer JR, et al. Lipid association increases the potency against primary medulloblastoma cells and systemic exposure of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ( CCNU ) in rats [ J ].Pharm Res, 1999, 16:896-903.
  • 4Mercadal M, Domingo JC, Petriz J, et al. A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-gaffed PEG chains[J]. Biochim Biophys Acta, 1999, 1418:232-238.
  • 5Versluis AJ, Rump ET, Rensen PC, et al. Synthesis of a lipophilic daunoruvicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy[J]. Pharm Res, 1998,15:531-537.
  • 6Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies[J]. Bioconjug Chem, 1999, 10:289-298.
  • 7Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs[J]. Curr Pharm Des, 1999, 5:443-451.
  • 8Ogawa Y, Kawahara H, Yagi N, et al, Synthesis of a novel lipopeptide with alpha-melanocyte-stimulating hormone peptide ligand and its effect on liposome stability[J]. Lipids, 1999, 34:387-394.
  • 9Krebber A, Bomhauser S, Burmester J, et al. Reliable cloning of functional antibody variable domains from hybfidoraas and spleen cell repertoires employing a reengineered phage display system[J]. J Immunol Methods, 1997, 201:35-55.
  • 10Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells[J]. Adv Drug Deliv Rev,2000, 41 : 171-188.

共引文献12

同被引文献12

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部